


ACR Convergence 2023: Top abstracts in psoriasis and psoriatic arthritis

To help navigate the exciting content being presented at the American College of Rheumatology (ACR) annual meeting (ACR Convergence 2023), we have provided recommendations for the top abstracts to look out for in psoriasis and psoriatic arthritis.



Psoriasis and Psoriatic Arthritis Hub



This educational resource is supported through funds from pharmaceutical companies—a full list of our supporters can be found at <https://psoriasis-hub.com/>. All content is developed independently by SES in collaboration with the faculty. The funders are allowed no influence on the content of this resource.

To help navigate the exciting content being presented at the American College of Rheumatology (ACR) annual meeting (ACR Convergence 2023), we have provided recommendations for the top abstracts to look out for in psoriasis and psoriatic arthritis:

Psoriasis	
2255	<u>Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: Results from the BE RADIANT phase 3b trial</u>
1920	<u>A phase Ib/II randomized, double-blind, placebo-controlled study of novel anti-IL-17A monoclonal antibody JS005 in patients with moderate to severe psoriasis</u>
1418	<u>Efficacy of the oral, selective, allosteric tyrosine kinase 2 inhibitor, deucravacitinib, on psoriasis in patients with active PsA: Results from a phase 2 trial</u>
0261	<u>Deucravacitinib in plaque psoriasis: 3-year safety and efficacy results</u>
0443	<u>The potential of an oral TNFα inhibitor with TNFR1 specificity: Results of a phase 1b proof-of-mechanism trial in psoriasis</u>

Psoriatic arthritis	
1433	<u>Bimekizumab impact on core group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA) domains for patients with psoriatic Arthritis: 52-week results from four phase 3 studies</u>
1422	<u>Long-term safety of risankizumab in patients with psoriatic disease: Integrated analysis of psoriasis and psoriatic arthritis clinical trial data</u>
L12	<u>Efficacy and safety outcomes of TAK-279, a selective oral tyrosine kinase 2 (TYK2) inhibitor, from a randomized, double-blind, placebo-controlled phase 2b trial in patients with active psoriatic arthritis</u>
0485	<u>Sex and treatment-associated outcomes in patients with active psoriatic arthritis treated with deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in a phase 2 trial</u>
0776	<u>Efficacy and safety of intravenous secukinumab for the treatment of active psoriatic arthritis: 16- and 52-week results from a randomized, double-blind, phase 3 study</u>



Follow us on X to keep up
to date with the latest
from ACR Convergence
2023

@psoriasis_hub
#ACR23

<https://psoriasis-hub.com/>

https://www.instagram.com/psoriasis_hub/